# Sichuan Zhishan Weixin Biotechnology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sichuan-zhishan-weixin-biotechnology

- Industry: Biotechnology
- Headquarters: Chengdu, China
- Latest round: Series B (Dec 10, 2025)
- Investors on record: 14

## About

Based in Chengdu, China and founded in 2018, Sichuan Zhishan Weixin Biotechnology Co., Ltd., trading as Sichuan Zhishan Weixin Biotechnology, is a company developing original new drugs for gene therapy, focusing on the development of original new drugs for rAAV gene therapy. The company has several patents and technologies in gene expression cassette design and vector production optimization, while the founder, Prof. Biao Dong, has been engaged in rAAV research for years. The company's core staff has rich experience in gene therapy drug design, preclinical research, and CMC development. In December 2025, Sichuan Zhishan Weixin Biotechnology raised a series B+ funding from new investor Chengdu Science and Technology Venture Capital Group, and other investors.
The company is mainly developing original new drugs for rAAV gene therapy, with a pipeline in development covering multiple clinical indications such as hematology, central nervous system, and metabolic system. The company's first self-developed product is ZS801, an gene therapy product for hemophilia B, which has received clinical approval in August 2022. The company also has a novel pox-adenovirus rAAV production system.
The company generates revenue from providing original new drugs for gene therapy.

## Funding rounds

- Series B, Dec 10, 2025 — Chengdu Science and Technology Venture Capital Group
- Series B, Jul 21, 2025 — BIO-TOWN Capital, SBI Chengdu
- Series A, Feb 1, 2023 — Panlin Capital, Loyal Valley Capital, SDIC Venture Capital, Essence Capital
- Series A, Feb 9, 2021 — 5Y Capital, Delian Capital, Loyal Valley Capital, Shanghai Junshi Biosciences Co., Ltd., Sichuan Venture Capital, Leimerious
- Angel, Nov 28, 2018 — Korea Investment Partners, Sichuan Venture Capital, Chengdu Tianfu International Bio-Town Investment & Development Co., Ltd.

## Investors

- Korea Investment Partners (https://capitalatlas.ai/funds/korea-investment-partners) — Angel
- Sichuan Venture Capital (https://capitalatlas.ai/funds/sichuan-venture-capital) — Angel, Series A
- Chengdu Tianfu International Bio-Town Investment & Development Co., Ltd. — Angel
- 5Y Capital (https://capitalatlas.ai/funds/5y-capital) — Series A
- Delian Capital (https://capitalatlas.ai/funds/delian-capital) — Series A
- Loyal Valley Capital (https://capitalatlas.ai/funds/loyal-valley-capital) — Series A
- Shanghai Junshi Biosciences Co., Ltd. — Series A
- Leimerious — Series A
- Panlin Capital (https://capitalatlas.ai/funds/panlin-capital) — Series A
- SDIC Venture Capital (https://capitalatlas.ai/funds/sdic-venture-capital) — Series A
- Essence Capital — Series A
- BIO-TOWN Capital (https://capitalatlas.ai/funds/bio-town-capital) — Series B
- SBI Chengdu (https://capitalatlas.ai/funds/sbi-chengdu) — Series B
- Chengdu Science and Technology Venture Capital Group (https://capitalatlas.ai/funds/chengdu-science-and-technology-venture-capital-group) — Series B